trial · primary record
Retlirafusp alfa + nab-paclitaxel + apatinib
Gastric Cancer (Diagnosis)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 32 |
| Primary completion | 2030-02-28 |
| Primary endpoint | 1-year OS rate |
| Registry ID | NCT07904442 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:36.193Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07904442
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.